Completed PHASE2 INTERVENTIONAL 4-arm NCT01764854

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis

Sponsor: Ardelyx

Conditions Chronic Kidney Disease Stage 5 ESRD End Stage Renal Disease

Interventions AZD1722 (in-patient) AZD1722 (out-patient) Placebo Placebo (in-patient)

Updated 7 times since 2017 Last updated: Aug 6, 2020 Started: Jan 31, 2013 Primary completion: Oct 31, 2013 Completion: Oct 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01764854, this PHASE2 trial focuses on Chronic Kidney Disease Stage 5 and ESRD and remains completed. Sponsored by Ardelyx, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2020 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ardelyx
AstraZeneca

Data source: Ardelyx

For direct contact, visit the study record on ClinicalTrials.gov .

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials